Aastrom Biosciences Inc., which develops stem cell-based tissue-regeneration products, said Wednesday its third-quarter loss widened 37 percent as expenses increased, and announced it can now start
making products at its German plant.
The Houston Chronicle
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
FDA Clears Coronary Artery Disease Intervention Planner
The device allows physicians to consult prior to the procedure and visualize the treatment path.
FDA Offers More Time to Join Quality Metrics Feedback Program
The agency proposes to use what it learns from the program to improve risk-based inspections.
FDAnews Drug Daily Bulletin
AASTROM 3Q LOSS WIDENS 37 PERCENT
May 11, 2006
